hsa-miR-200

ncRNA information

ncRNA name

hsa-miR-200

Specific or universal ncRNAs

Specific ncRNAs

Class

MicroRNA

Biomarker

No

Biomarker application

Upstream regulatory factors

Jagged2

Downstream target

Not available

Cancer information

Cancer name

Triple-Negative Breast Cancer

Cancer site

Breast

Treatment information

Treatment type

Chemotherapy

Drug

Paclitaxel

Impact of wild-type ncRNA on chemotherapy resistance

Impact of knockdown of ncRNA on chemotherapy resistance

Down

Impact of overexpression of ncRNA on chemotherapy resistance

Clinical Information

ncRNA differential expression in
cancer patients vs. healthy people

Not available

Number of patients

Not available

Male patients

Not available

Female patients

Not available

Age range and number

Not available

Research information

PMID

Description

Knockdown of Jagged2 inhibited CSC properties and paclitaxel resistance, whereas upregulated microRNA-200 expression.

Tissue resource

breast cancer tissues of patients diagnosed with triple-negative breast cancer

triple-negative breast cancer cell lines MDA-MB-231

Experiment

qRT-PCR,Western blot


Institute

Fujian Medical University Affiliated MinDong Hospital

Country

China

Continent

Asia